Phase II Study of Oxaliplatin and Taxotere in Metastatic Bladder Cancer

Inclusion Criteria

- Patient Population Type: Advanced Muscle Invasive Bladder Cancer

- Prior Therapy: One prior therapy for advanced disease

- Disease: Measurable disease

- ECOG Performance: 0,1

- Indication: Histologically Proven Carcinoma of the bladder

- For female patient of childbearing potential, neither pregnant nor breastfeeding, and
under active contraception

- Allergies: No known allergy to one of the study drugs

- Patient Status:

- No CNS metastases

- No peripheral neuropathy > grade1

- No other serious concomitant illness

- Fully recovered from any prior therapy

- Informed Consent: Patient and doctor have signed informed consent

- Lower Age Limit: Lower age limit >18

- Upper Age Limit: Upper Age Limit <70

- ANC: ANC >1500/mm3 or WBC > 3000/mm3

- Platelets: Platelets >100,000/mm3

- Creatinine: Creatinine <1.8mg/dL

- Bilirubin: Bilirubin <=2.0 x ULN

- SGPT: SGPT (ALT) <=1.5 x ULN (<4xULN if liver metastases present)

- RBC: Hemoglobin > 9.0g/dL

- Cardiovascular: No active congestive heart failure, no uncontrolled angina, no
myocardial infarction within the past 6 months

- Patients with metastatic cancer of the urothelial tract (TCC, Adenocarcinoma)

- No prior exposure to Oxaliplatin

- No cytotoxics or radiation 4 weeks prior to enrolling on protocol

- PT/PTT normal